Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study

INTRODUCTION: FOLFOXIRI plus bevacizumab has a promising efficacy as first-line systemic chemotherapy for metastatic colorectal cancer (mCRC). This study aimed to evaluate the safety and effectiveness of FOLFOXIRI plus antibodies. RESULTS: Fifty-five patients were enrolled (median age: 60 years, mal...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogata, Takatsugu, Satake, Hironaga, Ogata, Misato, Hatachi, Yukimasa, Maruoka, Hayato, Yamashita, Daisuke, Hashida, Hiroki, Hamada, Madoka, Yasui, Hisateru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383688/
https://www.ncbi.nlm.nih.gov/pubmed/30800219
http://dx.doi.org/10.18632/oncotarget.26626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383688/
https://www.ncbi.nlm.nih.gov/pubmed/30800219
http://dx.doi.org/10.18632/oncotarget.26626

Ejemplares similares